Giacomo Nuvola

Sep 18, 2023 | futuremedicine.com | Giacomo Nuvola |Veronica Mollica |Francesco Massari |Cristina Suarez |Cristina Suárez

The advent of immunotherapy has revolutionized the landscape of treatment in several cancers, with renal cell carcinoma (RCC) being one of the most responsive to this therapy [1]. This therapeutic approach is based on the complex interaction between the cancer and the immune system. It begins with cancer cells activating the innate and adaptive immune systems, resulting in tumor cell death.